SBIR/STTR Research Award

Drug Interactions in vitro for EP055: a Non-Hormonal Male Contraceptive

Award identifier a9383ceb64400350e926c89cf7060f4e06942ecc53ca96c6b61f4a65cdae8bb3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EPPIN PHARMA INC
Proposal award date
2018-12-17
Contract end date
2020-11-30
UEI
VHJQLGNL9T58
Solicitation number
HD19-004
Topic code
NICHD

Research abstract

Project Summary The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characteristicsnamely ease of usehigh efficacyreversibility and no side effectsthat differentiates it favorably from all the other male contraceptive competitorsAn important high impact driver of this market is the prevalence of unintended pregnanciesIn the US there aremillion unintended pregnancies annually through inconsistent or non use of contraceptionEppin Pharma will be competing in the short term contraception marketThe goal of EPPIN PHARMA INC is to develop a non hormonal male contraceptive drug that targets the protein EPPINwhich is present on the human sperm surfaceUnlike hormonal contraception which inhibits spermatogenesis our therapeutic agentEPis present in epididymal fluid and binds to EPPIN on the surface of sperminhibiting sperm motilityThe target EPPIN is only present in the malein testisepididymisand on spermthereby reducing non specific binding concernsThe Specific Aims of this SBIR proposal are designed to complement STTR phasedata and initiate metabolic and transporter studies of EPwhich are needed before first in human studies can beginIt is crucial to determine if EPwill have significant drug drug interaction before proceeding further because the male contraceptive would be taken by a healthy population of men or womenOur goal in this SBIR phase I application is to collect additional pharmacology data that will support and facilitate the completion of an IND application to the FDASpecific aimwill determine if EPis a substrateinhibitoror inducer of cytochrome PSpecific Aimwill determine if EPis a substrateor inhibitor of a transporterThis aim will evaluate transporters that are predominantly in the intestineliverkidneys and blood brain barrierSpecific aimwill analyze and document our drug manufacturing processscale up for production of EPto support future nonclinical and clinical studies Relevance to Public Health This research proposal is relevant to public health because it will develop a new male nonhormonal contraceptive that will enhance family planning throughout the world and give men and women additional contraceptive choicesCurrently men are limited in their options for contraception to condoms and vasectomyTherefore a non hormonal male contraceptive will fill an unmet need in contraceptionThis proposal is designed to develop a drug for male contraception that targets EPPIN and will initiate metabolic and transporter studies of EPwhich are needed before first in human studies can begin

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2015–2021). Reported award amounts total $3,577,756. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.